Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Monday, Evercore ISI analysts reiterated an Outperform rating for Vera Therapeutics stock (NASDAQ: VERA), maintaining a price target of $75.00 - significantly above the current trading price of $18.95. According to InvestingPro data, analyst consensus remains strongly bullish with targets ranging from $26 to $100. The analysts are optimistic about the company’s preparations for an FDA meeting regarding accelerated approval and the publication of results expected in the second half of 2025.
The analysts noted that the upcoming data could enhance enrollment in ongoing studies, including the PIONEER basket studies, which involve various renal indications. This development is seen as a positive step for Vera Therapeutics as it advances its research and development efforts. InvestingPro analysis shows the company maintains a strong financial position with a healthy current ratio of 27.68 and more cash than debt on its balance sheet.
Additionally, the Evercore ISI team mentioned their plans to attend the ERA event this week, where Otsuka’s Phase 3 results for sibeprenlimab, another B cell modulator, are scheduled to be presented on Friday in Vienna. The presentation will include a live event with a webcast option.
Sibeprenlimab, which has already been filed for U.S. approval, is expected to enter the market 6-9 months before atacicept. Phase 2 data showed a 43% reduction in proteinuria using a once-monthly IV infusion, while Phase 3 employed a 2ml subcutaneous injection, which could impact tolerability and compliance.
In other recent news, Vera Therapeutics has reported positive results from its ORIGIN Phase 3 trial of atacicept, a potential treatment for immunoglobulin A nephropathy (IgAN). The trial achieved a 46% reduction in proteinuria from baseline and a 42% reduction compared to placebo at week 36, indicating a significant advancement in IgAN treatment. Vera Therapeutics plans to engage with the FDA soon, with the aim of submitting a Biologics License Application for accelerated approval in the fourth quarter of 2025. Despite the positive trial results, the company posted a wider-than-expected net loss of $0.81 per share for the first quarter of 2025, exceeding analyst estimates by $0.08. The net loss expanded to $51.7 million compared to $28.4 million in the same quarter last year. Cantor Fitzgerald has maintained its Overweight rating on Vera Therapeutics with a $100 price target, reflecting confidence in the company’s future prospects. The firm’s analysis included discussions with kidney disease specialists, highlighting the potential of atacicept to meet unmet needs in IgAN treatment. Vera Therapeutics continues to focus on expanding atacicept’s development across multiple autoimmune kidney diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.